The case for & against
Bull & Bear analysis
Bullish
Amgen Inc. (NASDAQ:AMGN) is a leading biotechnology company that focuses on discovering, developing, and delivering human therapeutics in areas of unmet medical need. With a strong portfolio of innovative drugs, Amgen holds a dominant position in the biopharmaceutical market, particularly known for its treatments in oncology, cardiovascular, and metabolic disorders. The company is actively involved in the cardiometabolic space with its drug candidate MariTide, as well as in autoimmune diseases, making it a critical player in the ongoing healthcare and obesity management themes.
Bull says
- ↑Q2 2026 revenue $10.1B (+10% YoY) and EPS $6.29 topped estimates.
- ↑Full-year 2026 revenue guidance raised to $38.2–$39.4B on product strength.
- ↑Repatha and Evenity drove double-digit growth across 22 products.
- ↑MariTide Phase 3 obesity trial shows significant market potential.
- ↑Leverage remains conservative, supporting strategic investments without excessive debt.
- ↑Dividend yield 0.73% and high earnings yield attract income investors.
Bear says
- ↓Shares trade ~8% above $360 fair value estimate, risking correction.
- ↓Short interest remains elevated, reflecting significant market skepticism.
- ↓Analysts are trimming growth and earnings forecasts amid negative revisions.
- ↓Recent cybersecurity breach poses legal, reputational and operational risks.
- ↓Discontinuation of a weight-loss candidate narrows obesity pipeline.
- ↓Declining institutional holdings may reduce share demand and liquidity.
Investment themes with AMGN
High Dividend Yield↓ -0.51%
Companies paying above-average dividends
AVGO · JPM · XOM
Biotech